Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment

NCT06662877 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

NOT_YET_RECRUITING

Status

206

Enrollment

OTHER

Sponsor class

Conditions

Biliary Tract Cancer
Second Line Treatment
Chemotherapy
Tyrosine Kinase Inhibitor

Interventions

DRUG: Albumin-bound Paclitaxel + Tegafur Gimeracil Oteracil (S-1) + Anlotinib
DRUG: Oxaliplatin + Leucovorin + Fluorouracil (FOLFOX regimen)

Sponsor

Sun Yat-sen University

Collaborators

[object Object]